Aldeyra The (NASDAQ: ALDX) — Perfil da empresa, notícias e dados financeiros
Aldeyra Therapeutics develops therapies for immune-mediated diseases, focusing on ocular and systemic conditions.
Aldeyra The
Aldeyra Therapeutics (NASDAQ:ALDX) is a biotechnology firm focused on the discovery, development, and commercialization of therapies for immune-mediated diseases. Their projects are primarily centered on addressing ocular and systemic conditions by controlling inflammatory and immune responses, aiming to meet unmet medical needs in these areas. Aldeyra's pipeline includes candidates for the treatment of dry eye disease, allergic conjunctivitis, and other serious health conditions. Their objectives revolve around leveraging their proprietary RASP (Reactive Aldehyde Species) technology platform to bring novel treatments to patients, aiming to improve quality of life through scientific innovation and effective therapeutic solutions. With a commitment to excellence in research and patient care, Aldeyra is dedicated to advancing its projects from clinical development to commercial success.
Resumo
Operações
Produtos e/ou serviços de Aldeyra The
- Reproxalap, a novel, first-in-class treatment aimed at reducing inflammation for eye diseases including dry eye disease and allergic conjunctivitis.
- ADX-2191, an injectable formulation for the treatment of retinal diseases, including proliferative vitreoretinopathy.
- Clinical programs focused on treating systemic immune-mediated diseases by targeting RASP (reactive aldehyde species).
- Development of novel therapies aimed at rare skin disorders, leveraging unique mechanisms of action.
- Research on the application of their technology platform for the treatment of lung and other diseases caused by inflammation and immune dysregulation.
- Partnerships aimed at the expansion and diversification of their RASP-targeting therapeutic portfolio.
equipe executiva do Aldeyra The
- Todd C. BradyCEO, President & Director
- Michael AlfieriHead of Finance and Principal Financial & Accounting Officer
- David BurkeHead of Investor Relations
- Laura NicholsOperations Manager
- Adam LazorchakDirector of Translational Sciences & Non-Clinical Development
Principais indicadores financeiros
Resultados divulgados pela Aldeyra The, em USD.
- Cap. de mercado
- 41,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -35,3 mi | -33,8 mi | |
| 0 | -60,1 mi | -55,9 mi | |
| 0 | -42,8 mi | -37,5 mi | |
| 0 | -62,7 mi | -62 mi |